🏛️ FDA Clears CBD Path for Medicare as Missouri Hemp Ban Heads to Governor

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today's edition is sponsored by Forward Future AI and IgniteIT Spotlight: Ohio Valley. Use promo code POLICYDECODED20 for 20% off registration. See you there? Their support keeps these briefings free and focused on what actually matters.

The federal government moved two pieces at once this week. FDA told the market it will stand down on certain enforcement for CBD products inside a narrow Medicare pilot. CMS activated the program on April 1st with five participating ACOs. A lawsuit landed hours before launch. In Missouri, seven hours of filibuster pressure produced a hemp bill that effectively ends intoxicating hemp sales outside dispensaries. Georgia is rewriting bills on the fly to cut THC limits. Virginia is hiring regulators before the governor has signed the retail law. And in New York, the legislator who wrote the state's reinvestment promise is publicly questioning where the money is going. The thread running through today's stack is follow-through: who is building, who is still promising, and who just changed the rules.

💊 Medicare CBD pilot launches under lawsuit
🔥 Missouri hemp ban survives the Senate floor
📝 Virginia hires before the ink dries

FDA Commissioner Marty Makary issued a two-page memo on April 1st saying the agency will not enforce certain premarket approval and labeling requirements for orally administered hemp-derived CBD products used inside CMS's new Substance Access Beneficiary Engagement Incentive. The incentive went live the same day. Five Accountable Care Organizations in ACO REACH and the Enhancing Oncology Model submitted implementation plans. Participating organizations can furnish eligible hemp products to Medicare beneficiaries under physician supervision, up to $500 per year. Medicare itself does not pay for the product. This is not broad CBD access. It is a carefully bounded pilot tied to clinician direction, specific Innovation Center models, and a reimbursement structure that keeps the federal government one step removed from direct payment. The broader CBD marketplace remains unsolved. Hours before launch, a coalition led by Smart Approaches to Marijuana filed suit in D.C. District Court (SAM et al. v. Kennedy et al.) to block the program. A federal judge denied the emergency TRO and set a hearing for April 20th. The tension nobody in the room has resolved: the November 12th federal hemp definition change could make the covered products noncompliant within months. (Marijuana Moment)

🔥 Missouri's Hemp Bill Hits Kehoe's Desk After A Real Floor Fight

Rep. Dave Hinman's bill banning intoxicating hemp products from mainstream retail passed the House 126-23 and cleared the Senate Tuesday night. It is now on Gov. Mike Kehoe's desk. The path there was not smooth. Sen. David Gregory (R) initially brought a competing version that would have made the ban effective immediately upon signing. Sen. Karla May (D) ran a nearly seven-hour filibuster against it, and when that stalled, the chamber pivoted back to Hinman's bill, which aligns the effective date with the federal November 12th deadline. The legislation caps hemp products at 0.4 milligrams of THC per container and reclassifies intoxicating hemp-derived products as marijuana, pushing production, testing, and sales exclusively through the licensed dispensary system. State officials estimated in 2024 that more than 40,000 restaurants, bars, and smoke shops were selling covered products. Even if Congress later reverses course and allows broader hemp commerce, Missouri would still require those sales to move through dispensaries. The Senate added amendments granting collective bargaining rights to indoor cannabis cultivation and processing workers (Sen. Stephen Webber) and consumer privacy protections. Kehoe cited the legislation as a priority during his January State of the State. Because most hemp-derived products are grown outside Missouri and state law requires dispensary products to come from state-licensed facilities, this is effectively a ban. (Missouri Independent)

🗳️ Texas Democrats backed legalization and low-level expungement by roughly 80 percent on a primary ballot proposition. It does not change state law, but it keeps reinforcing the gap between where voters are willing to go and where Texas leadership has been willing to meet them. (Marijuana Moment)

🧪 The minor-cannabinoid push says as much about market maturity as it does about science. Brands are chasing more precise consumer use cases through CBN and THCV, but the evidence base still trails the marketing language by a fair margin. (Rolling Stone)

President Trump is reportedly weighing whether to replace Attorney General Pam Bondi with EPA Administrator Lee Zeldin. The temptation is to overread the personalities. Bondi may not have entered the job as a natural ally of cannabis reform, but she works for a president who made his preference on rescheduling clear in a December executive order. That same dynamic applies to any successor in an administration where cabinet-level independence has obvious limits. The more honest read is that rescheduling was already waiting behind tariffs, fiscal fights, and geopolitical maneuvering. DOJ had been moving the cannabis process in the background even as those larger battles consumed the administration's bandwidth. New leadership can alter timing, staffing, and internal ownership. But the risk here is bureaucratic disruption, not ideological reversal. (MJBizDaily)

Georgia senators took HB 34, originally a continuing education bill, and rewrote it to lower the legal THC limit in hemp beverages from 10 milligrams to 5 milligrams per drink. The rewritten version passed the Senate Committee on Regulated Industries and Utilities, which tells you lawmakers wanted a vehicle more than they wanted a clean legislative record. A separate proposal from Sen. Bill Cowsert (R-Athens) also targets the 10-to-5 reduction and would restrict sales to liquor stores. Georgia is a particularly interesting place for this fight. It has only a medical cannabis market, with SB 220 still awaiting Gov. Brian Kemp's action. The state may end up seeing a form of broader adult-use access through hemp beverage demand long before lawmakers are willing to say so plainly. That makes the dosage debate bigger than a number on a label. (WRDW)

🏥 Gov. Jared Polis signed SB 26-007, allowing terminally ill patients to use medical marijuana in Colorado healthcare facilities, while openly criticizing the amendment that lets facilities opt out. Polis called the opt-out a departure from the bill's original intent. Jim Bartell, whose son Ryan inspired patient-access laws now known as Ryan's Law in several states, urged lawmakers during hearings to restore the mandatory language. A state can recognize patient need and still leave families at the mercy of institutional caution. (Marijuana Moment)

🏀 Shawn Kemp is making a familiar normalization argument in a more useful way, pointing athletes toward cannabis topicals and recovery products rather than smoking. That does not move policy, but it shows where mainstream acceptance keeps growing first: pain management, wellness, and recovery. (Basketball Network)

The Florida Supreme Court dismissed Smart & Safe Florida's appeal on March 9th, ending the campaign's push to put recreational cannabis on the 2026 ballot. Smart & Safe fell short at 783,592 valid signatures against the 880,062 threshold. The shortfall followed months of state action that stripped tens of thousands of petitions: roughly 200,000 tossed for not including the amendment's full text, about 42,000 from voters classified as inactive, and nearly 29,000 collected by out-of-state gatherers during a window when a federal court injunction had stayed the law prohibiting them. Attorney General James Uthmeier's Office of Statewide Prosecution opened 46 criminal investigations into petition circulators and arrested or issued warrants for nine. Smart & Safe says it reported the suspect circulators to authorities itself. None of this is shocking given the DeSantis administration's $35-to-$45 million campaign against the 2024 cannabis and abortion amendments. The real question is downstream. Uthmeier wants to be seen, and the more public this becomes, the easier it is for other states to borrow the rhetoric if they want to tighten citizen initiative rules. Under a new election law, the signatures Smart & Safe collected will not carry over into 2028. (Marijuana Moment)

New York set aside 40 percent of cannabis tax revenue for communities harmed by the drug war. Five years after legalization, the visible return is one completed grant round: $5 million across 50 nonprofits for mental health, workforce development, and housing. A second round is now open with $5 million minimum and up to $15 million available pending the enacted budget, applications due May 13th. Total fund to date: $10 million. Assembly Majority Leader Crystal Peoples-Stokes, who championed the MRTA for eight years before it passed, told Spectrum News she is not satisfied with where the money is landing. She warned that the structure risks sending resources to organizations that write the best grants rather than to the communities that absorbed the most harm. She envisions future funding going beyond nonprofits to support community infrastructure directly. A promise this large starts to lose moral force when the money arrives slowly and lands diffusely. (Spectrum News)

Three dispensary companies, GP6 Wellness, RJK Holdings, and CCS of Alabama, hold licenses and are building out nine locations from Birmingham to Mobile to Athens. Former AMCC Chairman Rex Vaughn said before his departure that dispensaries could open by late April or early May. Vaughn stepped down after Gov. Ivey appointed him Madison County Commission Chairman in March. A fourth licensee, Yellowhammer Medical Dispensaries, remains in litigation with its license stayed. The launch will be limited: as of early March, only five physicians were licensed to recommend, though 20 had been certified by the Board of Medical Examiners. Dispensaries cannot sell flower, smokable products, or edibles. MJBizFactbook projects $270 million in first-year sales. After nearly five years of lawsuits, voided licensing rounds, and false starts since Gov. Ivey signed the medical cannabis law in 2021, tangible rollout work is finally happening. (AL.com)

🥤 Mayor Muriel Bowser wants D.C. breweries and distilleries to partner with licensed medical marijuana manufacturers on cannabis-infused nonalcoholic beverages, with sales staying inside the medical system. Members of Congress may soon find themselves debating hemp and THC beverages nationally while a regulated version of the category develops at their doorstep. (Axios)

Virginia's Cannabis Control Authority is posting roles for licensing director, compliance and enforcement director, compliance and enforcement manager, cannabis equity business loan administrator, and several others. Most application windows close this Sunday or April 12th. This is happening days before Gov. Abigail Spanberger's April 13th deadline to act on the adult-use sales legislation (SB 542 / HB 642), which passed the General Assembly in March and sets retail sales for January 1, 2027. Spanberger has not formally signed. She could propose amendments, which lawmakers would address when they reconvene April 22nd. New agencies do not build themselves. The team is the infrastructure. The team builds the capacity, the systems, the procedures, and the habits that make rollout work. That was true in Massachusetts. This is more than a personnel note. It is an early signal of whether the state intends to treat implementation as a real buildout or a talking point. (Marijuana Moment)

Georgia physicians are pressing Gov. Brian Kemp to veto SB 220, the Putting Georgia's Patients First Act, which passed the House 144-21. The bill would replace the 5 percent THC cap with a 12,000-milligram cumulative limit, permit vaping for registered patients 21 and older, rename "low-THC oil" to "medical cannabis," and add conditions including lupus and severe insomnia. The Georgia Access to Medical Cannabis Commission itself reported that the "low-THC oil" label discouraged patients from enrolling. Georgia's existing framework has long felt like a program designed to reassure skeptics more than serve patients. The broader arc points in a constructive direction if cannabis becomes more integrated into healthcare and less stranded in a symbolic low-THC box. That will bring friction. It may also bring a better system. (WSB-TV)

Nantucket is trying to halt ACK Natural's use of licensed courier Social-J for on-island cannabis deliveries, arguing the service violates local zoning and the dispensary's Host Community Agreement. ACK Natural and Social-J say the town is overreaching, pointing to state law and CCC guidance they believe authorize courier activity in municipalities that already permit marijuana sales. This is another test of whether towns can use HCAs and zoning to squeeze state-authorized cannabis activity after the state created the lane. Social-J is a social equity operator, which means the dispute touches the state's credibility when local enforcement collides with the access pathways Massachusetts said it wanted to build. (Inquirer and Mirror)

Maine lawmakers are moving LD 1847 to require batch testing and seed-to-sale tracking in the state's medical cannabis program, still the only one in the country operating without those safeguards. Supporters see it as overdue public-health cleanup after years of concern that bad actors could use the lightly regulated medical side as cover. Opponents see another compliance regime that squeezes smaller operators and rewards scale. Both concerns are real. If a state wants to call a program medical, it needs a defensible answer for why purity testing is optional. But lawmakers own the burden of making sure reform does not become a quiet consolidation tool. (Portland Press Herald)

Ohio lawmakers talk about guardrails and cleanup, but patients and consumers feel these decisions through price, taxes, and access. Medical patients still avoid the 10 percent adult-use excise tax, meaning the state already draws a cost distinction between therapeutic use and the broader retail market. That might look modest in a committee room. It feels different at the register, especially in a state that has spent the past year tightening rules on hemp products, possession, and product categories. The practical question is not whether Ohio has legal cannabis. It is how expensive lawmakers intend to make legal participation compared with the alternatives. (Dayton Daily News)